A Phase 1 interventional study of PALI-2108 in Fibrostenotic Crohn's Disease, sponsored by Palisade Bio. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by Palisade Bio · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Crohn Disease with a site in Canada — 50 open to participants now, 79 under way, 26 of them phase 3. Crohn Disease · Canada.
Among the 286 studies in Crohn Disease with a site in Canada, this one is the 227th largest by planned enrollment of the 238 interventional ones that give a count, is one of 14 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 14 of the 78 other live ones, and was the 279th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →50 of the 286 studies in Crohn Disease with a site in Canada are open now. Recruiting first, the newest first:
AbbVie · Sites in Canada, United States, Israel and 2 more countries
Ages 18–75
Janssen Research & Development, LLC · Sites in Canada, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Belgium and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Canada, United States, Belgium and 7 more countries
Ages 18–80
University of British Columbia · Sites in Canada
Ages 9–17
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 76 · Phase 3 97 · Phase 4 21
First in 2001; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 145 across the 238 interventional studies, 225 across the 45 observational. Of the 186 that completed or were terminated, 98 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 286 have an industry lead sponsor. The 10 most frequent:
Palisade Bio is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Palisade Bio has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
28 of the studies in Crohn Disease with a site in Canada that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 28 to your calendar (.ics) → With an account.
Among the 286 studies in Crohn Disease with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD). The study will assess molecular, cellular, and histologic changes in intestinal tissue and peripheral blood following short-term oral administration of PALI-2108.
Eligible participants with FSCD will undergo paired ileal pinch biopsies and peripheral blood collection at baseline and after 14 days of PALI-2108 treatment. The primary objective is to elucidate the mechanism of action of PALI-2108 in modulating inflammatory and fibrotic pathways relevant to FSCD pathobiology. Analyses will include single-nucleus RNA sequencing (snRNA-seq) of intestinal biopsies and single-cell RNA sequencing (scRNA-seq) of PBMCs to profile treatment-induced transcriptomic changes across immune and stromal cell populations.
The FSCD cohort is part of a larger, multi-part study that also includes a completed Phase 1a first-in-human portion in healthy volunteers and an ulcerative colitis (UC) cohort evaluating clinical and biomarker responses to PALI-2108 treatment.
This Phase 1b exploratory study will investigate the pharmacodynamic and mechanistic effects of short-term oral administration of PALI-2108, a selective phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD). The FSCD cohort builds upon the safety, tolerability, and pharmacokinetic findings from the completed Phase 1a first-in-human study and complements the ongoing ulcerative colitis (UC) cohort that assesses clinical and biomarker responses to PALI-2108 in active disease.
Fibrostenotic Crohn's disease is characterized by chronic inflammation and progressive fibrosis of the intestinal wall leading to luminal narrowing, strictures, and obstructive symptoms. Current medical therapies inadequately address the fibrotic component of disease, underscoring the need for interventions targeting both immune and stromal pathways. PDE4 inhibition represents a validated anti-inflammatory approach with emerging evidence for modulation of profibrotic signaling.
In this study, patients with ileal or ileocolonic FSCD will receive PALI-2108 orally once daily for 14 days. Paired ileal pinch biopsies and peripheral blood samples will be collected at baseline (Day 1) and at the end of treatment (Day 14). The primary objective is to characterize molecular and cellular changes induced by PDE4 inhibition in intestinal and immune compartments.
Transcriptomic profiling will be performed using single-nucleus RNA sequencing (snRNA-seq) on intestinal biopsies and single-cell RNA sequencing (scRNA-seq) on peripheral blood mononuclear cells (PBMCs). Analyses will evaluate treatment-associated changes in gene expression, cell-type composition, and pathway activation, with a focus on immune, epithelial, fibroblast, and myofibroblast populations implicated in FSCD pathology. Secondary and exploratory endpoints will include assessment of safety, tolerability, pharmacokinetics, and biomarker correlations across tissue and blood compartments.
Data from this FSCD cohort are expected to provide mechanistic insights into the biological effects of PDE4 inhibition in fibrostenotic disease and to inform dose selection, biomarker strategies, and patient segmentation for subsequent clinical development programs of PALI-2108.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
This study's planned enrollment of 6 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Palisade Bio is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If male, meets one of the following criteria:
Is able to procreate and agrees to use one of the accepted regimens and not to donate sperm from the first study drug administration to at least 90 days after the last study drug administration. An acceptable method of contraception includes one of the following:
If female, meets one of the following criteria:
Is of and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:
Use of 1 highly effective method in combination with 1 effective method of contraception.
Male partner vasectomized at least 6 months prior to the Screening visit
Diagnosis of ileal or ileocolonic CD based on supporting guideline criteria established at least 3 months prior to Screening, i.e.:
c) Clinically symptomatic fibrostenosing Crohn's disease, defined by ≥1 obstructive symptom attributable to the index ileal stricture within the prior 12 weeks and corroborated at Screening by the Stricturing Crohn's Disease patient-reported questionnaire (SPRO).
d) Symptoms must be accompanied by an ileal stricture within reach of the endoscope.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PALI-2108 All participants receive once-daily oral PALI-2108 for 14 days in the fed state. Two sentinel subjects receive a titrated regimen from 5 mg to 20 mg. After 7 days of sentinel dosing, the Safety Review Committee (SRC) reviews safety data and assigns the subsequent two patients to a target dose of 25 mg, with a predefined titration schedule. If the 25 mg dose is judged to be safe, all remaining subjects receive a target daily dose of 30 mg, also with a predefined titration scheme. Dose reductions may occur if safety profile is not judged adequate by SRC. Dosing is site-administered except on protocol-specified days when self-administration at home is permitted.
Drug: PALI-2108
Oral PALI-2108 administered once daily for 14 days. Sentinel subjects titrate from 5 mg to 20 mg. Subsequent patients receive a target dose between 10-30 mg based on SRC review, following protocol-specified titration schedules. Dose reductions are permitted for safety. All doses are taken in the fed state. PALI-2108 is an oral, gut-activated PDE4 inhibitor prodrug designed to release its active metabolite (PALI-0008) locally via bacterial β-glucuronidase. This targeted delivery limits systemic exposure and reduces CNS-related effects associated with systemic PDE4 inhibitors, providing localized anti-inflammatory and anti-fibrotic activity in intestinal tissue.
Safety and tolerability of PALI-2108 administered for 14 days.
Adverse events in FSCD patients receiving PALI-2108
Time frame: 14 days
Safety and tolerability of PALI-2108
Incidence of clinically significant laboratory abnormalities
Time frame: 14 Days
Safety and tolerability of PALI-2108
Incidence of clinically significant ECG findings
Time frame: 14 Days
Safety and tolerability of PALI-2108
Incidence of clinically significant vital signs findings
Time frame: 14 Days
Maximum Concentration (Cmax)
Maximum plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708 ) following dosing with PALI-2108
Time frame: Day 1
Concentration at 12 hours (C12)
Plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) at 12 hours following dosing with PALI-2108
Time frame: Day 1
Time to Cmax (Tmax)
Time to reach maximum plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708)
Time frame: Day 1
Area under the plasma concentration-time curve (AUC0-24)
Area under the plasma concentration-time curve of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) during the first 24 hours period after first dosing with PALI-2108
Time frame: Day 1
Terminal half-life (t1/2)
Plasma elimination half-life of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) after first dose of PALI-2108
Time frame: Day 1 and Day 13
Trough plasma concentration (Ctrough)
Plasma concentration of PALI-2108 and its metabolites (PALI-0008 and PALI-070) measured in the morning, before PALI-2108 dosing
Time frame: Day 2 through Day 14
Maximal concentration at steady state (Css)
Maximal plasma concentration of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) measured at plasma drug steady state
Time frame: Day 13
Area under the plasma concentration-time curve (AUC0-12)
Area under the plasma concentration-time curve of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) during the first 12 hours period after dosing with PALI-2108
Time frame: Day 13
Area under the plasma concentration-time curve (AUC0-8)
Area under the plasma concentration-time curve of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) during the first 8 hours period after last dosing with PALI-2108
Time frame: Day 14
Tissue concentration
Concentrations of of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) in ileal, ascending and descending colonic tissue at plasma steady state.
Time frame: Day 14
Tissue/plasma concentration ratio
Ratio between tissue and plasma concentrations of PALI-2108 and its metabolites (PALI-0008 and PALI-0708) in ileal, ascending and descending colonic tissue at plasma steady state.
Time frame: Day 14
Change in PDE-4 expression and related molecular pathways in ileal tissue.
Expression of inflammatory and fibrotic biomarkers via snRNA-seq and bulk RNA-seq (log fold change)
Time frame: Baseline to Day 14.
Change in endoscopic severity using the Simple Endoscopic Score for Crohn's Disease (SES-CD).
Change in endoscopic severity using the Simple Endoscopic Score for Crohn's Disease (SES-CD).
Time frame: Screening to Day 14 ileocolonoscopy
Change in intestinal ultrasound (IUS) parameters of ileal strictures (inflammatory and fibrotic features).
Change in intestinal ultrasound (IUS) parameters of ileal strictures (inflammatory and fibrotic features).
Time frame: Baseline to Day 13
Change in symptom scores based on the Stricturing Crohn's Disease Questionnaire (SPRO v1.0).
Change in symptom scores based on the Stricturing Crohn's Disease Questionnaire (SPRO v1.0).
Time frame: Screening to Day 13
Changes in fibrosis and inflammation biomarkers in plasma.
hsCRP, CPa9-HNE, PRO-C3, PRO-C6, PRO-C11, PRO-C16, XTX-III\_HP, C3M\_HP, C4M\_HP, C7M, PRO-C22, VICM\_HP, and transcriptomic signatures from PBMC mRNA-seq
Time frame: Baseline to Day 13.
Change From Baseline in Histology Score Using Robarts Histology Index (RHI) in ileum biopsy tissue
The RHI is an evaluative index, derived from the Geboes score and is designed to be reproducible and responsive to clinically meaningful change in disease activity over time. The total RHI score ranges from 0 (no disease activity) to 33 (severe disease activity). A negative change from baseline indicates improvement.
Time frame: Baseline to Day 14
Change From Baseline in Histology Score Using Nancy Histology Index (NHI) in ileum biopsy tissue
NHI is a validated index for assessing histological disease activity in UC. It is composed of three histological items defining five grades of disease activity: absence of significant histological disease (Grade 0), chronic inflammatory infiltrate with no acute inflammatory infiltrate (Grade 1), mildly active disease (Grade 2), moderately active disease (Grade 3), and severely active disease (Grade 4). The presence of ulceration on the biopsy specimen corresponds to severely active disease (Grade 4). A decrease of the NHI grading system to Grades 0 or 1 would indicate improvement.
Time frame: Baseline to Day 14
Change From Baseline in Histology Score Using Global Histologic Disease Activity Score (GHAS) in ileum biopsy tissue
GHAS is a validated histologic scoring assessment that evaluates the overall severity of mucosal inflammation in ulcerative colitis based on microscopic features (e.g., architectural distortion, chronic inflammatory infiltrate, neutrophils, erosions/ulceration). Minimum score: 0, Maximum score: 22. Higher scores indicate greater histologic disease activity.
Time frame: Baseline to Day 14
Change From Baseline in Ileum Biopsy Tissue Histological Assessment of Fibrocytes/Fibroblasts
The assessment measures the density and distribution of stromal cells involved in extracellular matrix production, wound healing, and fibrotic remodeling. There is no fixed minimum or maximum value. Higher values indicate increased stromal activation or fibrogenic activity.
Time frame: Baseline to Day 14
Change From Baseline in Ileum Biopsy Tissue Histological Assessment of Collagen
The assessment measures the extent and distribution of extracellular matrix collagen as an indicator of tissue remodeling or fibrotic activity. There is no fixed minimum or maximum value. Higher values reflect greater collagen accumulation.
Time frame: Baseline to Day 14
Change From Baseline in Ileum Biopsy Tissue Histological Assessment of Muscularis Mucosa Thickening
This measure reflects structural remodeling of the mucosal wall, often associated with chronic inflammation, altered motility, or early fibrotic change. There is no fixed minimum or maximum value. Higher values indicate greater thickening of the muscularis mucosa.
Time frame: Baseline to Day 14
Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD)
The SES-CD is a validated endoscopic scoring system that quantifies the severity of Crohn's disease based on colonoscopy findings. The minimum score is 0 (no endoscopic disease activity); the maximum score is 56 (severe ulceration, extensive affected surface, strictures in all segments).
Time frame: Baseline to Day 14
Change From Baseline in intestinal ultrasound (IUS) parameters of ileal strictures (inflammatory and fibrotic features)
IUS assessment of ileal strictures relies on quantitative measures (e.g., bowel wall thickness) and semi-quantitative features. The units are mm with higher values indicating more severity.
Time frame: Baseline to Day 14
Change From Baseline in symptom scores based on the Stricturing Crohn's Disease Questionnaire (SPRO v1.0)
The Stricturing Crohn's Disease Patient Reported Outcome (SPRO v1.0) is a validated PRO instrument developed by the STAR Consortium to measure symptoms and impacts associated with small bowel strictures in Crohn's disease. The instrument has a unitless score ranging from 0 (no symptoms) to 12 (worst symptoms).
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including
The Stricturing Crohn's Disease Patient Reported Outcome (SPRO v1.0) is a validated PRO instrument developed to measure symptoms and impacts associated with small bowel strictures in Crohn's disease. The instrument has a unitless score ranging from 0 (no symptoms) to 12 (worst symptoms).
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum High Sensitivity C Reactive Protein (hsCRPp)
hsCRP units of measure are mg/L with higher values indicating worse systemic inflammation.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Neutrophil Elastase-Degraded Type IX Collagen Fragment (Cpa9-HNE)
CPa9-HNE units of measure are ng/mL with higher values indicating worse neutrophil-driven tissue injury.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Type III Collagen Formation Fragment (PRO-C3)
PRO-C3 units of measure are ng/mL with higher values indicating worse collagen III formation / fibrogenesis.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Type VI Collagen Formation Fragment (Endotrophin) (PRO-C6)
PRO-C6 units of measure are ng/mL with higher values indicating worse collagen VI formation / fibrosis.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Type XI Collagen Formation Fragment (PRO-C11)
PRO-C11 units of measure are ng/mL with higher values indicating worse collagen XI formation / remodeling.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Type XVI Collagen Formation Fragment (PRO-C16)
PRO-C16 units of measure are ng/mL with higher values indicating worse collagen XVI formation / basement membrane remodeling.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Cross Linked Type III Collagen Fragment (High Precision) (XTX-III_HP)
XTX-III\_HP units of measure are ng/mL with higher values indicating worse cross linked collagen III turnover.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum MMP Degraded Type III Collagen Fragment (High Precision) (C3M_HP)
C3M\_HP units of measure are ng/mL with higher values indicating worse MMP mediated collagen III degradation.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum MMP Degraded Type IV Collagen Fragment (High Precision) (C4M_HP)
C4M\_HP units of measure are ng/mL with higher values indicating worse MMP mediated collagen IV degradation; basement membrane injury.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum MMP Degraded Type VII Collagen Fragment (C7M)
C7M units of measure are ng/mL with higher values indicating worse collagen VII degradation; epithelial barrier injury.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Type XXII Collagen Formation Fragment (PRO-C22)
PRO-C22 units of measure are ng/mL with higher values indicating worse collagen XXII formation; epithelial-stromal interface remodeling.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers Including Serum Citrullinated And MMP Degraded Vimentin Fragment (High Precision) (VICM_HP)
VICM\_HP units of measure are ng/mL with higher values indicating worse macrophage activation; citrullinated vimentin turnover.
Time frame: Baseline to Day 13
Change From Baseline In Biomarkers in PBMC and FSCD lesions (inflammatory region and fibrotic region including Whole Blood Composite Gene Expression Signature)
Transcriptomic signatures use a unitless composite score with no fixed range, The change of values is gene dependent and can be indicating disease progression by change in either direction
Time frame: Baseline to Day 13
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Jan 2026, 3 months.
Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 3 months is below that.
Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PALI-2108
Palisade Bio